Denmark-based multinational pharmaceutical company Novo Nordisk will be making available in the Philippines within this year ...

Stevanato Group has created a scalable, customizable pen injector for the pharmaceutical industry, designed for use in areas including diabetes care, weight management and cardiovascular and ...

Insulin efsitora alfa (investigational once-weekly basal insulin): In another ADA-sponsored symposium, Lilly will share results from the QWINT-1, QWINT-3 and QWINT-4 Phase 3 trials, which evaluated ...

The researchers found that the risks for obesity-related cancers and all-cause death were lower during a mean follow-up of 3.9 years (adjusted hazard ratios, 0.93 and 0.92, respectively) in ...

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the GLP-1 space, Novo Nordisk markets its semaglutide drugs under brand names ...

There are some caveats — people must pay out of pocket, or the medication is sold in a vial rather than a prefilled injector pen. And the financial barriers remain: $400 to $500 is a significant ...

There are some caveats — people must pay out of pocket, or the medication is sold in a vial rather than a prefilled injector pen — but doctors and patients say the changes are long overdue.